Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Advancing translational research through the NHLBI Gene Therapy Resource Program (GTRP).

McDonald CL, Benson J, Cornetta K, Diggins M, Johnston JC, Sepelak S, Wang G, Wilson JM, Wright JF, Skarlatos SI.

Hum Gene Ther Clin Dev. 2013 Mar;24(1):5-10. doi: 10.1089/humc.2013.036. Epub 2013 Apr 3. Review.

2.

National Heart, Lung, and Blood Institute and the translation of cardiovascular discoveries into therapeutic approaches.

Galis ZS, Black JB, Skarlatos SI.

Circ Res. 2013 Apr 26;112(9):1212-8. doi: 10.1161/CIRCRESAHA.113.301100.

3.

Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN).

Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, March KL, Murphy MP, Pepine CJ, Simari RD, Skarlatos SI, Traverse JH, Willerson JT, Szady AD, Taylor DA, Vojvodic RW, Yang PC, Moyé LA; Cardiovascular Cell Therapy Research Network.

Circulation. 2013 Apr 16;127(15):1630-5. doi: 10.1161/CIRCULATIONAHA.112.000779. No abstract available.

4.

Bone marrow-derived cell therapy after myocardial infarction.

Moyé LA, Simari RD, Skarlatos SI; Cardiovascular Cell Therapy Research Network (CCTRN).

JAMA. 2013 Apr 10;309(14):1459. doi: 10.1001/jama.2013.2601. No abstract available.

5.

Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012.

O'Reilly M, Kohn DB, Bartlett J, Benson J, Brooks PJ, Byrne BJ, Camozzi C, Cornetta K, Crystal RG, Fong Y, Gargiulo L, Gopal-Srivastava R, High KA, Jacobson SG, Jambou RC, Montgomery M, Rosenthal E, Samulski RJ, Skarlatos SI, Sorrentino B, Wilson JM, Xie Y, Corrigan-Curay J.

Hum Gene Ther. 2013 Apr;24(4):355-62. doi: 10.1089/hum.2013.064.

6.

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

JAMA. 2012 Dec 12;308(22):2380-9. Erratum in: JAMA. 2013 Jan 23;309(4):343. Erratum in: JAMA. 2015 Jul 7;314(1):86.

7.

Center for fetal monkey gene transfer for heart, lung, and blood diseases: an NHLBI resource for the gene therapy community.

Tarantal AF, Skarlatos SI.

Hum Gene Ther. 2012 Nov;23(11):1130-5. doi: 10.1089/hum.2012.178. Epub 2012 Oct 19. Review.

8.

Support for cardiovascular cell therapy research at the National Heart, Lung, and Blood Institute.

Buxton DB, Skarlatos SI.

Circ Res. 2012 Jun 8;110(12):1549-55. doi: 10.1161/RES.0b013e31825ec2a3. Review. No abstract available.

PMID:
22679137
9.

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

JAMA. 2012 Apr 25;307(16):1717-26. doi: 10.1001/jama.2012.418. Epub 2012 Mar 24. Erratum in: JAMA. 2015 Jul 7;314(1):86.

10.

Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study.

Richman S, Gee AP, McKenna DH, Traverse JH, Henry TD, Fisk D, Pepine CJ, Bloom J, Willerson JT, Prater K, Zhao D, Koç JR, Anwaruddin S, Taylor DA, Cogle CR, Moyé LA, Simari RD, Skarlatos SI.

Transfusion. 2012 Oct;52(10):2225-33. doi: 10.1111/j.1537-2995.2011.03543.x. Epub 2012 Feb 10.

11.

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy ResearchNetwork.

JAMA. 2011 Nov 16;306(19):2110-9. doi: 10.1001/jama.2011.1670. Epub 2011 Nov 14.

12.

Oversight and management of a cell therapy clinical trial network: experience and lessons learned.

Moyé LA, Sayre SL, Westbrook L, Jorgenson BC, Handberg E, Anwaruddin S, Wagner KA, Skarlatos SI.

Contemp Clin Trials. 2011 Sep;32(5):614-9. doi: 10.1016/j.cct.2011.05.003. Epub 2011 May 17.

13.

Current NHLBI perspectives on translational heart failure research.

Lathrop DA, Skarlatos S.

J Mol Cell Cardiol. 2011 Oct;51(4):441-3. doi: 10.1016/j.yjmcc.2010.09.026. Epub 2010 Oct 11. No abstract available.

PMID:
20946899
14.

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD; Cardiovascular Cell Therapy Research Network.

Tex Heart Inst J. 2010;37(4):412-20.

15.

Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design.

Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, Gee A, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

Am Heart J. 2010 Aug;160(2):215-23. doi: 10.1016/j.ahj.2010.03.029.

16.

Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience.

Gee AP, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J, Prater K, Zhao D, Koç JR, Ellis S, Taylor D, Cogle C, Moyé L, Simari R, Skarlatos S.

Cytotherapy. 2010 Sep;12(5):684-91. doi: 10.3109/14653249.2010.487900.

17.

Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN).

Simari RD, Moyé LA, Skarlatos SI, Ellis SG, Zhao DX, Willerson JT, Henry TD, Pepine CJ.

J Cardiovasc Transl Res. 2010 Feb;3(1):30-6. doi: 10.1007/s12265-009-9160-3.

18.

Translational research for cardiovascular diseases at the National Heart, Lung, and Blood Institute: moving from bench to bedside and from bedside to community.

Lauer MS, Skarlatos S.

Circulation. 2010 Feb 23;121(7):929-33. doi: 10.1161/CIRCULATIONAHA.109.917948. Review. No abstract available.

19.

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

Am Heart J. 2009 Sep;158(3):356-63. doi: 10.1016/j.ahj.2009.06.009. Epub 2009 Jul 23. Erratum in: Am Heart J. 2009 Dec;158(6):1045. Vaughn, Douglas E [corrected to Vaughan, Douglas E].

20.

The Extramural Division of Cardiovascular Sciences of the National Heart, Lung, and Blood Institute.

Lauer MS, Skarlatos SI, Bild DE.

J Am Coll Cardiol. 2009 Jul 14;54(3):265-8. doi: 10.1016/j.jacc.2009.04.025. No abstract available.

21.

New programs for gene- and cell-based therapies at NHLBI.

Skarlatos SI.

Clin Pharmacol Ther. 2007 Sep;82(3):334-6. Epub 2007 Jul 11. Review.

PMID:
17625516
22.

National Heart, Lung, and Blood Institute resources and programs for gene therapy in heart, lung, and blood diseases.

Skarlatos SI.

Circ Res. 2007 Jun 22;100(12):1667-9. No abstract available.

PMID:
17585073
23.

Critical resources for gene therapy in Heart, Lung, and Blood Diseases Working Group.

Woo SL, Skarlatos SI, Joyce MM, Croxton TL, Qasba P; Heart, Lung, and Blood Diseases Working Group.

Mol Ther. 2006 Apr;13(4):641-3. No abstract available.

24.

Critical Resources for Gene Therapy in Heart, Lung, and Blood Diseases Working Group.

Woo SL, Skarlatos SI, Joyce MM, Croxton TL, Qasba P.

Mol Ther. 2006 Apr;13(4):641-643. doi: 10.1016/j.ymthe.2005.12.007. Epub 2006 Feb 2. No abstract available.

PMID:
28189018
25.

Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus.

Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, Skarlatos S, Wassef M, Rabadan-Diehl C; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus.

Circulation. 2005 Jun 28;111(25):3489-93. No abstract available.

PMID:
15983263
26.

Report of the National Heart, Lung and Blood Institute-National Institute of Allergy and Infectious Diseases working group on antimicrobial strategies and cardiothoracic surgery.

Lowy FD, Waldhausen JA, Miller M, Sopko G, Rosenberg Y, Skarlatos SI; National Heart, Lung and Blood Institute-National Institute of Allergy and Infectious Diseases working group on antimicrobial strategies and cardiothoracic surgery.

Am Heart J. 2004 Apr;147(4):575-81.

PMID:
15077070
27.
28.

Homocysteine: an emerging risk factor.

Skarlatos SI.

Ethn Dis. 2002 Winter;12(1):S1-38-40. No abstract available.

PMID:
11913618
30.

Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research.

Libby P, Egan D, Skarlatos S.

Circulation. 1997 Dec 2;96(11):4095-103. Review. No abstract available.

PMID:
9403635
31.

Accumulation of HDL apolipoproteins accompanies abnormal cholesterol accumulation in Schnyder's corneal dystrophy.

Gaynor PM, Zhang WY, Weiss JS, Skarlatos SI, Rodrigues MM, Kruth HS.

Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):992-9.

PMID:
8696964
32.

Transport of [125I]transferrin through the rat blood-brain barrier.

Skarlatos S, Yoshikawa T, Pardridge WM.

Brain Res. 1995 Jun 19;683(2):164-71.

PMID:
7552351
33.

Sequestration of acetylated LDL and cholesterol crystals by human monocyte-derived macrophages.

Kruth HS, Skarlatos SI, Lilly K, Chang J, Ifrim I.

J Cell Biol. 1995 Apr;129(1):133-45.

34.

Cholesterol efflux from human monocyte-derived macrophages in the presence of LpA-I:A-II.

Skarlatos SI, Duverger N, Rader D, Kruth HS.

Biochim Biophys Acta. 1995 Jan 25;1270(1):19-25.

35.
36.

Spontaneous changes in arterial blood pressure and renal interstitial hydrostatic pressure in conscious rats.

Skarlatos S, Brand PH, Metting PJ, Britton SL.

J Physiol. 1994 Dec 15;481 ( Pt 3):743-52.

38.

Spontaneous pressure-flow patterns in the kidney of conscious rats.

Skarlatos S, Metting PJ, Britton SL.

Am J Physiol. 1993 Dec;265(6 Pt 2):H2151-9.

PMID:
7904424
39.

Gravimetric method for the dynamic measurement of urine flow.

Steele JE, Skarlatos S, Brand PH, Metting PJ, Britton SL.

Proc Soc Exp Biol Med. 1993 Oct;204(1):70-4.

PMID:
8372099
40.

Spontaneous pressure-flow relationships in renal circulation of conscious dogs.

Skarlatos S, DiPaola N, Frankel RA, Pomerantz RW, Brand PH, Metting PJ, Britton SL.

Am J Physiol. 1993 May;264(5 Pt 2):H1517-27.

PMID:
8098913
41.

Absence of triglyceride accumulation in lipoprotein lipase-deficient human monocyte-macrophages incubated with human very low density lipoprotein.

Skarlatos SI, Dichek HL, Fojo SS, Brewer HB, Kruth HS.

J Clin Endocrinol Metab. 1993 Mar;76(3):793-6.

PMID:
8383147
42.

Heterogeneity of cellular cholesteryl ester accumulation by human monocyte-derived macrophages.

Skarlatos SI, Rouis M, Chapman MJ, Kruth HS.

Atherosclerosis. 1993 Mar;99(2):229-40.

PMID:
7684908
43.

Phospholipid loss in dying platelets.

Skarlatos SI, Rao R, Dickens BF, Kruth HS.

Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(4):241-5.

PMID:
8287120
44.

Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene.

Lohse P, Brewer HB 3rd, Meng MS, Skarlatos SI, LaRosa JC, Brewer HB Jr.

J Lipid Res. 1992 Nov;33(11):1583-90.

45.

Uptake of exogenous free cholesterol induces upregulation of tissue factor expression in human monocyte-derived macrophages.

Lesnik P, Rouis M, Skarlatos S, Kruth HS, Chapman MJ.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10370-4.

46.

Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome.

Chao FF, Blanchette-Mackie EJ, Tertov VV, Skarlatos SI, Chen YJ, Kruth HS.

J Biol Chem. 1992 Mar 5;267(7):4992-8.

47.

Identification of two separate allelic mutations in the lipoprotein lipase gene of a patient with the familial hyperchylomicronemia syndrome.

Dichek HL, Fojo SS, Beg OU, Skarlatos SI, Brunzell JD, Cutler GB Jr, Brewer HB Jr.

J Biol Chem. 1991 Jan 5;266(1):473-7.

48.

Lipoprotein lipaseBethesda: a single amino acid substitution (Ala-176----Thr) leads to abnormal heparin binding and loss of enzymic activity.

Beg OU, Meng MS, Skarlatos SI, Previato L, Brunzell JD, Brewer HB Jr, Fojo SS.

Proc Natl Acad Sci U S A. 1990 May;87(9):3474-8.

49.

Characterization of two unique cholesterol-rich lipid particles isolated from human atherosclerotic lesions.

Chao FF, Blanchette-Mackie EJ, Chen YJ, Dickens BF, Berlin E, Amende LM, Skarlatos SI, Gamble W, Resau JH, Mergner WT, et al.

Am J Pathol. 1990 Jan;136(1):169-79.

50.

Biochemical characterization of isolated cholesterol-phospholipid particles continuously released from rat and human platelets after activation.

Skarlatos SI, Amende LM, Chao FF, Blanchette-Mackie EJ, Gamble W, Kruth HS.

Lab Invest. 1988 Sep;59(3):344-52.

PMID:
3411935

Supplemental Content

Loading ...
Support Center